Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine

被引:55
作者
Emi, Y [1 ]
Tsunashima, D [1 ]
Ogawara, K [1 ]
Higaki, K [1 ]
Kimura, T [1 ]
机构
[1] Okayama Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Okayama 7008530, Japan
关键词
D O I
10.1021/js970294v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The intestinal transport of quinidine was characterized in rat small intestine, using the Ussing-type chamber under short-circuited conditions. In the short-circuited condition, quinidine transport was predominantly secretory and the transport rate in jejunum was 3.5 times larger in the secretory direction than that in the absorptive direction. The secretion of quinidine was found to be dependent upon its concentration and to be via a carrier-mediated system in both jejunum and ileum. Although the kinetic characteristic of the carrier-mediated secretion of quinidine was very similar in jejunum and ileum, its contribution was much greater in jejunum because of a higher passive diffusion component in ileum. The secretion of quinidine, well-known as an inhibitor of P-glycoprotein, was inhibited significantly and its absorption was enhanced significantly by several substrates of P-glycoprotein including verapamil, diltiazem, and digitoxin in jejunum. These phenomena were also observed by the addition of 2,4-dinitrophenol. Furthermore, the voltage-clamp studies indicated that the inhibition of quinidine secretion occurred in the transcellular pathway. On the other hand, neither tetraethylammonium nor p-aminohippuric acid affected the transport of quinidine. Quinidine was also recognized to inhibit the secretion and to promote the absorption of substrates of P-glycoprotein, chlorpromazine, and verapamil. These results strongly suggest that quinidine is not only an inhibitor but also a substrate of P-glycoprotein and that the P-glycoprotein-mediated secretory flux acts as a barrier to quinidine absorption in the small intestine, especially jejunum.
引用
收藏
页码:295 / 299
页数:5
相关论文
共 29 条
[11]  
LAUTERBACH F, 1983, INTESTINAL TRANSPORT, P76
[12]   INHIBITION OF INTESTINAL P-GLYCOPROTEIN AND EFFECTS ON ETOPOSIDE ABSORPTION [J].
LEU, BL ;
HUANG, JD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) :432-436
[13]  
LEVEQUE D, 1995, ANTICANCER RES, V15, P331
[14]  
OKAMURA N, 1993, J PHARMACOL EXP THER, V266, P1614
[15]   ESSENTIAL FEATURES OF THE P-GLYCOPROTEIN PHARMACOPHORE AS DEFINED BY A SERIES OF RESERPINE ANALOGS THAT MODULATE MULTIDRUG RESISTANCE [J].
PEARCE, HL ;
SAFA, AR ;
BACH, NJ ;
WINTER, MA ;
CIRTAIN, MC ;
BECK, WT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (13) :5128-5132
[16]   POSSIBLE INVOLVEMENT OF MULTIPLE P-GLYCOPROTEIN-MEDIATED EFFLUX SYSTEMS IN THE TRANSPORT OF VERAPAMIL AND OTHER ORGANIC CATIONS ACROSS RAT INTESTINE [J].
SAITOH, H ;
AUNGST, BJ .
PHARMACEUTICAL RESEARCH, 1995, 12 (09) :1304-1310
[17]   ION TRANSPORT IN ISOLATED RABBIT ILEUM .I. SHORT-CIRCUIT CURRENT + NA FLUXES [J].
SCHULTZ, SG ;
ZALUSKY, R .
JOURNAL OF GENERAL PHYSIOLOGY, 1964, 47 (03) :567-&
[18]  
SHINKEL AH, 1994, CELL, V77, P491
[19]  
SPARREBOOM A, 1997, P NATL ACAD SCI USA, V94, P203
[20]  
Su SF, 1996, DRUG METAB DISPOS, V24, P142